Recent advances of antibody drug conjugates for clinical applications
| Autor: | Wenqing Li, Pengxuan Zhao, Yizhou Dong, Christopher Jeanty, Yuebao Zhang, Guangya Xiang |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Oncology
medicine.medical_specialty Gemtuzumab ozogamicin Review Humanized antibody Antibody drug conjugates 03 medical and health sciences Linker 0302 clinical medicine Internal medicine medicine Cytotoxic agents General Pharmacology Toxicology and Pharmaceutics Brentuximab vedotin Anaplastic large-cell lymphoma Antibody 030304 developmental biology Inotuzumab ozogamicin 0303 health sciences business.industry lcsh:RM1-950 medicine.disease Metastatic breast cancer Clinical application Lymphoma body regions Clinical trial lcsh:Therapeutics. Pharmacology 030220 oncology & carcinogenesis business medicine.drug |
| Zdroj: | Acta Pharmaceutica Sinica. B Acta Pharmaceutica Sinica B, Vol 10, Iss 9, Pp 1589-1600 (2020) |
| ISSN: | 2211-3835 |
| Popis: | Antibody drug conjugates (ADCs) normally compose of a humanized antibody and small molecular drug via a chemical linker. After decades of preclinical and clinical studies, a series of ADCs have been widely used for treating specific tumor types in the clinic such as brentuximab vedotin (Adcetris®) for relapsed Hodgkin's lymphoma and systemic anaplastic large cell lymphoma, gemtuzumab ozogamicin (Mylotarg®) for acute myeloid leukemia, ado-trastuzumab emtansine (Kadcyla®) for HER2-positive metastatic breast cancer, inotuzumab ozogamicin (Besponsa®) and most recently polatuzumab vedotin-piiq (Polivy®) for B cell malignancies. More than eighty ADCs have been investigated in different clinical stages from approximately six hundred clinical trials to date. This review summarizes the key elements of ADCs and highlights recent advances of ADCs, as well as important lessons learned from clinical data, and future directions. Graphical abstract Antibody drug conjugates (ADCs), normally composed of a humanized antibody and small molecular drugs via chemical linkers, represent a rapidly growing field for cancer therapy. In this review, we provide an overview of ADCs in preclinical and clinical development, as well as future directions of ADCs.Image 1 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|